Resource utilisation and cost of cervical cancer and dysplasia in Croatia
Journal Title: European Journal of Gynaecological Oncology - Year 2019, Vol 40, Issue 1
Abstract
Purpose of investigation: To analyse resource utilisation and costs due to cervical cancer and dysplasia in Croatia. Materials and Methods: Patients diagnosed with cervical cancer were identified from the Croatian National Cancer Registry. Resource utilisation and costs of cervical cancer treatment for the period of five years after the date of diagnosis were retrieved from the Croatian Health Insurance Fund Claims Database. Patients diagnosed with cervical dysplasia were identified and their resource utilisation and treatment costs during one year following diagnosis were obtained from the Croatian Health Insurance Fund Claims Database. Results were calculated for different healthcare services and disease stages. Results: There were 346 patients diagnosed with cervical cancer in 2008. Total costs of treatment in the five-year period were 2,177,071 Euros, while average cost of treatment per patient was 6,403 Euros. The largest shares of total costs were costs for hospitalisations (73%), followed by outpatient healthcare (17%), and personal sick leave (7%). There were also 14,913 patients with cervical dysplasia diagnosed in 2012. Total costs of their treatment during one year after the diagnosis were 1,609,073 Euros, with average costs per patient of 108 Euros. Outpatient care (48%), followed by hospitalisations (45%), and prescribed medicines (6%) had the greatest share of total costs. Conclusion: Treatment of cervical cancer and dysplasia in Croatia is associated with significant costs and healthcare resource utilisation.
Authors and Affiliations
A. Ivičević Uhernik, M. Vajagić, Z. Lovrić
Keywords
Related Articles
- EP ID EP626315
- DOI 10.12892/ejgo4210.2019
- Views 67
- Downloads 0
The role of erythropoietin and erythropoietin receptor expression in breast cancer
Erythropoietin (EPO) plays a number of important functions in the body. Contrary to original beliefs, its activity is not limited to exerting effects on cells along the erythropoietic pathway. Newly published results con...
Immunohistochemical analysis of IQGAP2 in ovarian cancer
IQ motif-containing GTPase-activating protein 2 (IQGAP2) was regarded as a tumor suppressor in some cancers, but its expression pattern in various histological subtypes of ovarian cancer has not been investigated. Immuno...
The differential gene expression of Notch receptors in primary and metastatic epithelial ovarian cancer sites
Purpose of Investigation: Notch signaling belongs among the candidate pathways for targeted therapies in ovarian cancer. While Notch 3 and Notch 1 overexpression has already been confirmed in ovarian carcinomas compared...
Plasma fibrinogen, CRP, and hs-CRP levels in patients with benign and borderline ovarian tumours
Objective: Ovarian tumours can be classified as benign, borderline or malignant lesions. The purpose of this study was to assess, inter alia, fibrinogen concentration, and the (C-reactive proteins) and high-sensitivity C...
Risk of cervical cancer and squamous intraepithelial lesions according to human papillomavirus high-risk serotypes detected by qualitative real-time in vitro PCR
Purpose of investigation: To establish the relationship between high-risk human papillomavirus (hrHPV) serotypes and the odds of developing cervical intraepithelial lesions. Material and Methods: Retrospective cohort stu...